A randomized, double masked, active controlled, phase III study of the efficacy and safety of repeated doses of intravitreal VEGF Trap-Eye in subjects with diabetic macular edema To assess the efficacy of intravitreally (IVT) administered VEGF Trap Eye in comparison to laser treatment in improving best corrected visual acuity (BCVA) in subjects with diabetic macular edema (DME...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Single-center, randomized, placebo-controlled, double-blind, parallel group study to evaluate whether a single-dose of either 20 mg piroxicam, 40 mg piroxicam or 80 mg piroxicam shows an effect on ovulation after the onset of LH surge compared to placebo in healthy young women To assess whether piroxicam has an effect on ovulation (delay or inhibition) when given after the onset of LH surge

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A double-blind, randomized, placebo and active controlled, multicenter study to investigate efficacy and safety after oral administration of 2 and 3 mg ZK 283197, 1 mg 17ß-estradiol and placebo once daily for 8 weeks in postmenopausal women with hot flushes To investigate the influence of a 8-weeks multiple dose treatment with two oral doses of ZK 283197 in comparison to E2 and placebo on the reduction of moderate to severe hot flushes

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

An investigator-blind, randomized, multicenter, 5-arm, placebo- and active controlled parallel group pilot trial to explore the efficacy and tolerability of topical bifonazole liquid spray in patients with athlete’s foot This explorative pilot trial will assess efficacy and safety of the new bifonazole liquid spray compared to placebo and the active comparator terbinafine film-forming solution (Lamisil Once®). Various...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Phase II randomized, double-blind, placebo-controlled study of sorafenib or placebo in combination with transarterial chemoembolisation (TACE) performed with DC Bead and doxorubicin for intermediate stage hepatocellular carcinoma (HCC) To demonstrate the superiority of sorafenib over placebo with regard to Time To Progression (TTP) in patients with intermediate stage HCC receiving TACE performed with DC Bead

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Rivaroxaban for treatment in venous thrombosis in children The primary objective is: • to assess the incidence of major bleeding and clinically relevant non-major bleeding

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A study to find out whether some PAH patients may benefit by replacing their current phosphodiesterase-5 inhibitors (PDE-5i) with or without endothelin receptor antagonist (ERA), with Riociguat Un estudio para averiguar si algunos pacientes con HAP pueden beneficiarse mediante la sustitución de sus actuales inhibidores de la fosfodiesterasa-5 (PDE-5i) con o sin antagonista del receptor de endotelina (ERA), con Riociguat To assess the proportion of patients in each treatment arm with a satisfactory clinical response as defined by a composite primary endpoint at Week 24. El objetivo principal es evaluar la propor...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

(REASON) double-blind, Randomized phase II study to Evaluate the safety and efficacy of Acetyl-l-carnitine in the prevention of SagOpilone-induced peripheral Neuropathy Primary Objective: to demonstrate the superiority of ALC over placebo in the prevention of Sagopilone-induced peripheral neuropathy

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Safety of Primovist / Eovist in Renally Impaired patients The primary objective is to assess the magnitude of potential risk of developing NSF with the administration of Primovist/Eovist in patients with moderate to severe renal impairment for the developmen...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Étude 18594 : étude de phase 1 évaluant la sécurité, la tolérance, les paramètres pharmacocinétiques et pharmacodynamiques et la dose maximale tolérée et/ou recommandée pour la phase 2 du BAY1895344 chez des patients ayant des tumeurs solides avancées et/ou des lymphomes. Les tumeurs solides peuvent se développer dans n’importe quel tissu : peau, muqueuses, os, organes, etc. Ce sont les plus fréquentes puisqu’elles représentent 90 % des cas de cancers. Un lymphome est...

• Pays France
• Organes Tumeurs solides, Lymphomes non hodgkinien
• Spécialités Thérapies Ciblées